First AD

Second AD

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

ESA Treatment Selection in MDS

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Evolving Treatment Landscape in Myelodysplastic Syndromes

Peer Exchange

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Cancer Centers

Partner

Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine

Diagnosis of Myelodysplastic Syndromes (MDS)

Risk Stratification of Myelodysplastic Syndromes

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

Patient Profile 1: A 72-Year-Old Man With MDS

Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

Patient Profile 2: A 77-Year-Old Man With MDS

Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

IMerge: Imetelstat in Patients With Lower-Risk MDS

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

Treatment Options and Unmet Needs in Higher-Risk MDS

Updates from ASH 2023 in Higher-Risk MDS

Takeaways from ASH 2023 in Higher-Risk MDS

Closing Thoughts on the MDS Treatment Landscape